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1ABSTRACT
Identification of evidence for autoimmune pathology of 
bilateral sudden sensorineural hearing loss using proteomic analysis
Jeon Mi Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Sung Huhn Kim)
Sudden sensorineural hearing loss (S-SNHL) is an inner ear disorder 
defined as a minimum of 30 dB hearing loss over 3 consecutive frequencies in 
a pure-tone audiogram occurring in less than 3 days. The pathologic 
mechanism of the disease remains unclear, although autoimmunity has been 
regarded as one of the suggested causes, especially in the bilateral form. In 
this study, we aimed to provide evidence for the involvement of autoimmune 
mechanisms in bilateral S-SNHL using proteomic approaches. 
A total of 10 patients with bilateral S-SNHL and 10 normal control subjects 
were enrolled for this study. First, in a ProtoArray®, 20 proteins showed more 
than 2-fold greater signal intensity in patients with bilateral S-SNHL than in 
the control subjects, which suggested the presence of circulating 
autoantibodies in the patients’ sera and their possible target antigens. Second, 
western blotting using the subjects’ sera and mouse inner ear protein, for the 
assessment of the antigen-antibody reactions between circulating 
autoantibodies and corresponding antigens in the inner ear, showed exclusive 
2bands of molecular weight 63–75 kDa and 35–48 kDa between patients’ sera 
and mouse inner ear. Third, liquid chromatography-mass spectrometry 
(LC-MS) / mass spectrometry (MS) using proteins extracted from the 
immunoprecipitation for the identification of the target antigen and 
autoantibody in the reaction revealed 8 overlapping proteins between the 
subjects’ sera and mouse inner ear that can serve as candidate antigens and/or 
autoantibodies. 
These findings provide evidence for autoimmunity as one of the 
pathological mechanisms for bilateral S-SNHL, and suggest candidate 
antigens and autoantibodies. 
--------------------------------------------------------------------------------------
Key words : bilateral sudden sensorineural hearing loss, autoimmune 
disease, inner ear, autoantibody
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I. INTRODUCTION
Sudden sensorineural hearing loss (S-SNHL) was first described by 
DeKleyn in 1944, and is defined by the National Institute on Deafness and 
other Communication Disorders as a minimum of 30 dB hearing loss over 3 
consecutive frequencies in a pure tone audiogram, occurring in less than 3 
days.1 The global incidence has been reported to be variable from 5 to 160 per 
100,000 individuals.2,3 While the disease has a wide age distribution with an 
average age at incidence of 50–60 years, it is equally distributed between 
sexes. The etiology and pathogenesis of S-SNHL remain unknown, although 
detailed investigations have revealed a specific cause such as viral infection, 
vascular occlusion, and immune system-mediated mechanisms only in about 
10% of the patients.4, 5
Although unilateral involvement is common (~95%) in S-SNHL, bilateral 
involvement can occur in less than 5% of the cases.6 Bilateral S-SNHL can be 
4further classified into simultaneous (i.e., the second ear is affected within 3 
days of the first ear) or sequential (the second ear is affected 3 or more days 
after the first ear) types.5 The 3 types of S-SNHL (unilateral, sequential 
bilateral, and simultaneous bilateral) were reported to have different severities 
of hearing loss at presentation, suspected etiologies, and prognoses.5 While 
unilateral cases showed improvement in the hearing threshold after systemic 
steroid treatment in ~65% of the patients, simultaneous bilateral S-SNHL is 
associated with a more severe degree of hearing loss at presentation, and is 
less responsive to treatment; retrocochlear lesions are usually common during 
the development of this disorder.7,8 Sequential bilateral S-SNHL and 
simultaneous bilateral S-SNHL without retrocochlear lesions have been 
reported to have variable prognoses since the incidence of the disorder is low 
and the etiology is not fully determined.5,7,9,10 Although various etiologies 
have been suspected for S-SNHL as described above, a definite cause for 
S-SNHL cannot be determined in most cases. Nevertheless, autoimmunity is 
strongly suspected as one of the causes for S-SNHL, especially for bilateral 
S-SNHL without evidence of retrocochlear lesions, based on its bilaterality 
and responses to steroid and immune-suppressive treatment in certain 
cases.5,11
Several findings have provided evidence that autoimmunity may underlie 
the pathological mechanism of bilateral S-SNHL. One of the factors 
supporting the involvement of an autoimmune mechanism is the molecular 
5evidence of the presence of immune cells and mediators in the inner ear of 
patients with bilateral S-SNHL as well as in animal models. Tissue infiltration 
and free-floating lymphocytes, plasma cells, and macrophages have been 
observed in the inner ear of patients with proliferation of fibrous tissue and 
destruction of adjacent bony structures.12 Animal models have also 
demonstrated similar inner ear damage with inflammatory reactions after 
immunization using the candidate antigens.13 Furthermore, elevation of
immune responses between animal inner ear proteins and serum samples 
obtained from patients with S-SNHL has been demonstrated.14 The fact that 
S-SNHL frequently occurs in context of systemic immune disease and that its 
symptoms can be improved with immunosuppressive therapy strongly 
supports the involvement of autoimmunity in the pathogenesis of bilateral 
S-SNHL.7,15,16
So far, several studies have been conducted to investigate various candidate 
antigens and autoantibodies (autoAbs) in bilateral S-SNHL. However, 
evidence for autoimmunity as a pathological mechanism of bilateral S-SNHL 
remains insufficient, as most studies have investigated selective target 
proteins instead of utilizing a mass screening approach, thus limiting the 
probability of detecting candidate whole autoAbs and their target antigens. 
Consequently, it was later revealed that findings related to some of these 
candidate proteins were not sufficiently quantified. For example, collagen 
type II had been proposed as a potential target antigen, although the reported 
6hearing loss associated with collagen type II immunization had not been 
reproduced consistently.17 In addition, heat shock protein-70 (HSP-70) was 
elevated in more than 35% of patients with autoimmune inner ear disease, but 
subsequent animal studies demonstrated no correlation between elevated 
anti-HSP antibody levels and pathological injury.18
In this study, we aimed to provide evidence for the involvement of 
autoimmunity in bilateral S-SNHL using proteomic approaches such as 
ProtoArray®, western blotting, immunoprecipitation, and liquid column mass 
spectrometry for the mass screening of candidate antigens and autoAbs based 
on the hypothesis that multiple autoAbs and target antigens must exist in order 
for autoimmune bilateral sudden hearing loss to develop. The results of this 
study may provide basic evidence necessary for the development of diagnostic 
biomarkers as well as the understanding of the pathological mechanisms 
underlying bilateral S-SNHL.
7II. METHODS
1. Selection of patients and controls
Ten patients diagnosed with bilateral S-SNHL according to the criteria of the 
National Institute on Deafness and other Communication Disorders were 
enrolled as the patient group. The mean age was 45.7 ±16.0 yr, and the 
men:women ratio was 5:5. Four patients had simultaneous attacks in both ears, 
while the other six experienced sequential attacks with an average interval of 
33.8 ±19.9 mo. Complete neurological examination and temporal magnetic 
resonance imaging (MRI) did not show any evidence of a central lesion. 
Detailed patient information is listed in Table 1.
Table 1. Patient demographics
Gender
/Age
Clinical 
features
Interval 
(mo)
250 
Hz
500 
Hz
1,000 
Hz
2,000 
Hz
3,000 
Hz
4,000 
Hz
8,000 
Hz
Average
P1 M/44 Sequential 36
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
55 55 60 40 40 60 95 53.8
2nd 
ear 60 65 70 65 70 75 105 68.8
Final hearing 
level 
(dB HL)
1st 
ear
50 55 60 45 50 70 90 57.5
2nd 
ear 55 65 65 65 75 70 100 66.3
P2 M/28 Simultaneous -
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
75 90 95 85 75 70 75 85.0
2nd 
ear
85 90 90 80 85 90 100 87.5
Final hearing 
level 
(dB HL)
1st 
ear
65 70 70 55 30 50 50 61.3
2nd 
ear
75 75 75 60 55 55 55 66.3
P3 M/30 Sequential 26
Pre-treatment 
hearing level 
(dB HL)
1st 
ear 25 30 40 45 40 45 20 40.0
2nd 
ear
20 25 35 50 50 55 50 41.3
Final hearing 
level 
(dB HL)
1st 
ear
20 25 45 45 40 40 20 38.8
2nd 
ear
30 30 35 40 45 45 45 37.5
P4 F/57 Simultaneous -
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
70 70 80 70 85 95 105 78.8
2nd 
ear 85 90 105 115 115 120 105 107.5
Final hearing 
level 
(dB HL)
1st 
ear
75 80 80 75 85 90 115 81.3
2nd 
ear 90 95 105 105 115 120 105 106.3
8P5 F/77 Sequential 22
Pre-treatment 
hearing level 
(dB HL)
1st 
ear 75 75 85 85 75 75 80 80.0
2nd 
ear
75 70 60 40 40 35 75 51.3
Final hearing 
level 
(dB HL)
1st 
ear
75 80 90 80 80 80 95 82.5
2nd 
ear
65 60 65 55 40 40 70 55.0
P6 M/60 Simultaneous -
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
65 55 60 35 45 55 65 51.3
2nd 
ear
60 70 90 105 120 100 100 91.3
Final hearing 
level 
(dB HL)
1st 
ear
35 20 15 15 20 20 35 17.5
2nd 
ear 50 75 85 95 115 100 105 88.8
P7 F/36 Sequential 16
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
40 40 25 25 25 30 30 30.0
2nd 
ear
10 10 15 5 25 45 45 18.8
Final hearing 
level 
(dB HL)
1st 
ear
5 5 5 5 0 10 10 6.3
2nd 
ear
15 25 25 10 40 50 20 27.5
P8 F/37 Sequential 72
Pre-treatment 
hearing level 
(dB HL)
1st 
ear 95 105 105 95 95 85 80 97.5
2nd 
ear
10 20 25 40 70 90 95 43.8
Final hearing 
level 
(dB HL)
1st 
ear 90 105 105 95 100 105 95 102.5
2nd 
ear
35 35 35 40 75 80 80 47.5
P9 F/55 Simultaneous -
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
65 70 70 105 100 100 90 86.3
2nd 
ear
65 85 75 75 75 70 80 76.3
Final hearing 
level 
(dB HL)
1st 
ear
60 70 80 110 105 105 90 91.3
2nd 
ear 15 35 35 35 40 40 65 36.3
P10 M/33 Sequential 31
Pre-treatment 
hearing level 
(dB HL)
1st 
ear
30 35 30 25 15 20 25 27.5
2nd 
ear
25 35 40 20 5 -5 -5 22.5
Final hearing 
level 
(dB HL)
1st 
ear
15 10 5 5 5 10 10 7.5
2nd 
ear
15 30 10 0 0 -5 -5 8.8
Uniform treatment was provided for all patients. All the patients underwent 
medical treatment within 24 hr of the onset of the hearing loss. 
Methylprednisolone was administered at a dose of 1 mg/kg per day for the 
first five days, and the dose was tapered over the next five days. After 10 days 
of treatment, the hearing level was evaluated by pure-tone audiometry. When 
the hearing level had not completely recovered (recovery of hearing to within 
10 dB of the previous hearing level), intratympanic dexamethasone injection 
was administered 5 times every other days. The mean follow-up period was 
932.0 ±26.7 mo, and none of the patients showed recurrent attacks during the
follow-up period. 
Ten volunteers who had no history of sensorineural hearing loss or vertigo, 
with audiograms showing normal hearing (average pure-tone audiometry less 
than 25 dB) were enrolled as the control group. None of the patients or control 
subjects had a history of systemic disease such as diabetes, hypertension, 
autoimmune disorder, and acute or chronic inflammatory disorders, and all of 
their laboratory parameters, including electrocardiography, chest radiography, 
blood cell counts (red blood cells, white blood cells, and platelets), liver and 
kidney function tests, and urine analysis were normal. The sex distribution 
and mean age of the patient and control groups did not significantly differ (p > 
0.05 for the chi-square test and t-test). 
2. Sampling of sera 
Blood was sampled from every participant in each group for the experiment. 
Peripheral blood was sampled before the administration of any medication 
and within 24 hours of the development of symptoms in the bilateral S-SNHL 
group. In the control group, blood was sampled immediately after obtaining 
informed consent. The blood was stored in a tube containing 
ethylenediaminetetraacetic acid (EDTA), the plasma was immediately 
separated, and stored at -80°C until further analysis. 
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3. ProtoArray® analysis of serum samples (Immune Response Biomarker 
Profiling)
To investigate the presence of possible antigen-antibody reactions between 
circulating autoAbs and their target antigens, and to identify candidate target 
antigens for the autoimmune reaction, the ProtoArray® (Human Protein 
Microarray v5.0 containing 9,400 human proteins, Invitrogen Corp., Carlsbad, 
CA, USA) analysis was performed with sera from patients and control 
subjects according to the manufacturer's protocol. Briefly, after blocking the 
array slides with blocking buffer for 1 hr, we washed the slides with washing 
buffer for 5 min, after which 5 ml of diluted serum (1∶500) was placed on the 
slides. The slides were incubated for 90 min and washed with washing buffer 
4 times for 5 min each. After the slides were washed, Alexa Fluor 647 (final 
concentration, 1μg/ml) was added to the slides, and the slides were incubated 
for 90 min. The antibody was aspirated, and the slides were washed 4 times 
for 5 min each. These steps were performed at 4°C. The slides were dried 
immediately by centrifugation at 200×g for 1 min and stored in a slide box to 
protect them from light until scanning was performed. The dried arrays were 
scanned using a GenePix 4,000B microarray scanner (Molecular Devices, 
Sunnyvale, CA, USA). The GenePix Pro microarray data acquisition software 
was used to align the scanned image with the template and to acquire the pixel 
intensity data for each spot on the array. The reported pixel intensity was 
calculated as the average of duplicate signals obtained after subtracting the 
11
background signal. The ProtoArray® Prospector software (Life Technologies, 
Carlsbad, CA, USA) was used to analyze the data, perform background 
subtraction, and normalize the signals. The normalized signal intensities 
obtained for controls and patients were compared using the t-test, and 
differences with a p value less than 0.05 were considered statistically.
4. Western blotting
To investigate whether circulating autoAbs in the patient serum reacted with 
inner ear tissue, western blotting using the patient serum and mouse inner ear 
tissue was performed. We used mouse inner ear tissue for ethical reasons as it 
would have been impossible to harvest the entire human cochlea and vestibule 
to use as fresh specimens for analysis. The entire temporal bone was separated 
from eight-week-old male C57BL/6 mice. The cochlea and vestibule were 
separated, and the membranous labyrinth was carefully dissected from the 
cochlea and vestibule. Each membranous labyrinth was lysed with 2× sample 
buffer (250 mM Tris-HCl [pH 6.5], 2% sodium dodecyl sulfate [SDS], 1% 
dithiothreitol [DTT], 0.02% bromophenol blue, and 10% glycerol). Protein 
levels were quantified by comparing the absorbance of the lysate with that of 
serially diluted bovine serum albumin (0, 0.2, 0.4, 0.6, 0.8, and 1 mg/ml) in a 
VersaMax enzyme-linked immunosorbent assay (ELISA) plate reader 
(Molecular Devices, Sunnyvale, CA, USA). Samples were heated for 5 min at 
95°C in 95% glycerol. The protein levels were quantified by comparing the 
12
absorbance of the lysate with that of serially diluted bovine serum albumin of 
the bands. The proteins were separated using a 10% SDS-polyacrylamide gel 
at 125 V for 4 hr with a running buffer (25 mM Tris-Base, 192 mM glycine, 
and 0.1% SDS) and transferred to polyvinylidene difluoride membranes 
(Millipore, Bedford, MA, USA) using a semi-dry transfer cell (Bio-Rad, 
Hercules, CA, USA) for 2 hr at 200 mA and a transfer buffer (10 mM 
Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 20). The membranes were 
blocked with 5% skim milk in Tris-buffered saline (TBS; 50 mM Tris-HCl 
[pH 7.5] and 150 mM NaCl) for 2 h at room temperature. The blots were 
incubated overnight with patient serum diluted at 1∶200 in 0.5% Tween-20 in 
TBS (TTBS). The blots were washed with TTBS, incubated with a secondary 
anti-human antibody (Cell Signaling Technology, Danvers, MA, USA) in 
TTBS for 45 min at room temperature, and visualized using enhanced 
chemiluminescence (Amersham Biosciences, Champaign, IL, USA).
5. Immunoprecipitation of sera 
Immunoprecipitation was performed to capture antigen-autoantibody 
(Ag-autoAb) complexes composed of mouse inner ear antigens and 
circulating autoAbs from the patients. The goal of the procedure was to 
provide Ag-autoAb complexes for liquid chromatography mass spectrometry 
(LC-MS)/ mass spectrometry (MS) to identify the inner ear antigens and 
circulating antibodies that react with each other. Eight-week-old male 
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C57BL/6 mice were used, and mouse inner ear tissue was prepared as 
described above. The quantified protein was incubated overnight with the 
human antibody at 4°C. Sepharose beads (P9,424 Protein A-Sepharose human 
antibody; Sigma-Aldrich, St. Louis, MO, USA) were added to 1-mL tubes 
containing the incubated samples and the tubes with the beads were incubated 
at 4°C for 2 hr. After incubation, the tubes were centrifuged at 10,000 rpm for 
30 sec to precipitate the beads. The supernatant was carefully removed 
completely with a pipette and the beads were washed 3 times with washing 
buffer (5 ml radioimmunoprecipitation assay buffer, 50 μ 
phenylmethylsulfonyl fluoride) to remove non-specific binding. For each 
wash, the beads were gently vortexed with washing buffer and centrifuged for 
precipitation, and the supernatant was discarded. Finally, 2× sample buffer 
was added to the sample and heated for 5 min at 99°C to elute the protein 
from the beads. After elution, the sample was centrifuged at 13,000 rpm for 30 
sec and the supernatant was collected for LC-MS/MS. 
6. One-dimensional electrophoresis (1-DE) and identification of candidate 
inner ear antigens for autoimmune reaction by LC-MS/MS
1-DE and LC-MS/MS were performed to analyze the inner ear antigens that 
react with circulating autoAbs of patients. 1-DE was performed with the 
samples acquired from the immunoprecipitation. The samples were 
lyophilized and dissolved in 15 μl of distilled water. The amount of protein in 
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each sample was quantified. A total of 6 μg of protein were subjected to 
SDS-polyacrylamide gel electrophoresis on an 8–16% Tris-glycine gel and 
stained with Coomassie Brilliant Blue. Bands corresponding to the molecular 
weight ranges of 63-75 kDa and 35-48 kDa, where the Ag-Ab reaction was 
most frequent in western blotting, were excised from the 1-DE gel. After 
reduction with DTT and alkylation with iodoacetamide, the bands were 
treated with trypsin for in situ digestion. The bands were then washed with 10 
mM ammonium bicarbonate and 50% acetonitrile and swollen in digestion
buffer containing 50 mM ammonium bicarbonate, 5 mM CaCl2, and 1 mg of 
trypsin. Next, they were incubated at 37°C for 12 hr. Peptides were recovered 
over the course of 2 extraction cycles with 50 mM ammonium bicarbonate 
and 100% acetonitrile. The resulting peptide extracts were pooled, lyophilized, 
and stored at -20°C.
Nano LC-MS/MS analysis was performed on an Agilent 1,100 Series 
nano-LC and linear trap quadrupole (LTQ)-mass spectrometer (Thermo 
Electron, San Jose, CA, USA). LC-MS/MS was performed on the sera 
obtained from four patients and four controls. The capillary column used for 
LC-MS/MS analysis (150 mm × 60.075 mm) was obtained from Proxecon 
(Odense M, Denmark) and slurry-packed in-house with 5 mg, 100 Å pore size 
Magic C18 stationary phase (Michrom Bioresources, Auburn, CA, USA). The 
mobile phase A for LC separation was 0.1% formic acid in deionized water 
and the mobile phase B was 0.1% formic acid in acetonitrile. Chromatography 
15
was performed using a linear gradient from 5% B to 35% B over 100 min, 
from 40% B to 60% B over 10 min, and from 60% B to 80% B over 20 min. 
The flow rate was maintained at 300 nl/min after splitting. Mass spectra were 
acquired using data-dependent acquisition with full mass scan (400–1800 
m/z) followed by MS/MS scans. Each acquired MS/MS scan represented the 
average of one microscan on the LTQ. The temperature of the ion transfer 
tube was controlled at 200°C and the spray was 1.5–2.0 kV. The normalized 
collision energy was set at 35% for MS/MS.
The MASCOT and SEQUEST (BioWorks software version 3.2, Thermo 
Electron) search engines were used to search the UniProt human protein 
database (release 14.8; 82728 sequences) for tandem mass spectra. Mass 
tolerances of 1.2 Da and 0.6 Da were used for the precursor and fragment ions, 
respectively. The search included variable modification of methionine 
oxidation and cysteine carbamidomethylation. PeptideProphet and 
ProteinProphet were used to estimate the false discovery rate (FDR) for any 
minimum probability used as a cut-off for the MASCOT and SEQUEST 
search results.
1-DE and LC-MS/MS were performed in 8 subjects (4 patients and 4 
controls) due to the time and cost effectiveness. Subject selection for these 
analyses was done based on the western blotting results. Only subjects who 
showed relatively higher responses were selected for these analyses.
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7. Ethics statement
This study was approved by the Institutional Review Board of the Severance 
Hospital (approval number 4-2011-0871), and written informed consent was 
obtained from all participants. The Institutional Animal Care and Use 
Committee of the Yonsei University College of Medicine approved this study, 
and all the mice were treated in accordance with the guidelines for the Care 
and Use of Laboratory Animals of the Yonsei University College of Medicine 
(approval number 2011-0084).
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III. RESULTS
1. Treatment response to corticosteroids in patients with bilateral 
S-SNHL 
Among 20 ears, 7 ears responded to the treatment (4 ears fully recovered, 
and 3 ears partially recovered), while the other 13 ears did not respond (Table
1). Patient 2 had simultaneous attacks in both ears, and did not respond to 
initial oral medication. After 5 rounds of salvage intratympanic injection after 
the oral medication treatment, the hearing in both ears partially improved. 
Patient 6 also experienced simultaneous attacks. One ear fully recovered after 
the administration of oral medication, but the other ear failed to recover even 
after the administration of intratympanic injection in addition to the oral 
medication. Patient 7 had sequentially occurring sudden hearing loss and the 
first ear fully recovered with oral medication, however, the second ear was 
resistant to both oral medication and intratympanic injection. Patient 9 
experienced simultaneous attacks, and only one ear partially recovered after 1 
cycle of oral medication; however, the patient refused further treatment. 
Patient 10 had sequential bilateral sudden hearing loss; the first ear fully 
recovered with oral medication, and the second ear recovered after an
additional intratympanic injection. 
2. Evidence of circulating autoAbs and candidate target antigens for 
autoimmune reaction identified by the ProtoArray® analysis
18
We investigated the presence of circulating autoAbs in the peripheral blood 
and their candidate target antigens of the 10 patients with bilateral S-SNHL 
using the Immune Response Biomarker Profiling application on the 
ProtoArray®. Twenty proteins were identified to have more than 2-fold greater 
signal intensity in patients with bilateral S-SNHL than in controls (p < 0.05, 
Table 2); the signal intensity of 7 proteins was more than 5-fold higher in 
patients than in controls (Table 2 and Figure 1). Among these proteins, 
C-X-C motif chemokine 10 (CXCL10) had the highest signal intensity, and 
was approximately 15-fold higher in patients than in controls. These results 
provide evidence for the existence of circulating autoAbs and enhanced 
autoimmune/immune reactions with the candidate target antigens in patients 
with bilateral S-SNHL.  
Table 2. Proteins with higher signal intensities in bilateral S-SNHL in 
ProtoArray® analysis 
Access No.
Swissprot 
ID
Protein name
Fold 
change
Function
NM_001565.1 P02778 C-X-C motif chemokine 10 15.6
Chemoattraction, promotion 
of T cell adhesion to 
endothelial cells, antitumor 
activity, and inhibition of 
bone marrow colony 
formation and angiogenesis. 
NM_005975.2 Q13882
PTK6 protein tyrosine 
kinase 6 (PTK6)
9.7
Regulation of signaling 
pathway that control the 
differrentiation and 
maintenance of normal 
epithelia 
BC045667.1 Q9Y5W8 sorting nexin 13 (SNX13) 9.1
Intracellular trafficking. May 
play a role in endosome 
homeostasis. Acts as a GAP 
for Galphas
NM_016127.4 Q96BY9
transmembrane protein 66 
(TMEM66)
6.9
Negative regulator of 
store-operated Ca2+ entry 
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(SOCE) involved in 
protecting cells from Ca2+ 
overfilling
NM_002984.1 P13236
chemokine (C-C motif) 
ligand 4 (CCL4), transcript 
variant 1
6.9
Monokine with inflammatory 
and chemokinetic properties. 
One of the major 
HIV-suppressive factors 
produced by CD8+ T-cells.
BC032456.1 Q5VYS8
zinc finger, CCHC domain 
containing 6 (ZCCHC6)
6.2
Mediates the terminal 
uridylation of mRNAs with 
short (less than 25 
nucleotides) poly(A) tails, 
hence facilitating global 
mRNA decay
NM_002059.3 P01242
growth hormone 2 (GH2), 
transcript variant 1
5.2
Growth control. It stimulates 
both the differentiation and 
proliferation of myoblasts. It 
also stimulates amino acid 
uptake and protein synthesis 
in muscle and other tissues.
NM_002982.1 P13500
chemokine (C-C motif) 
ligand 2 (CCL2)
4.3
Chemotactic factor that 
attracts monocytes and 
basophils but not neutrophils 
or eosinophils. 
BC044218.1 Q861E6
MHC class I 
polypeptide-related 
sequence B (MICB)
4
Seems to have no role in 
antigen presentation. Acts as a 
stress-induced self-antigen 
that is recognized by gamma 
delta T cells.
BC024021.1 Q9H4A9 *dipeptidase 2 (DPEP2) 3.9
Probable metalloprotease 
which hydrolyzes leukotriene 
D4 (LTD4) into leukotriene 
E4 (LTE4).
BC068602.1 Q96I99
Succinyl-CoA ligase 
[GDP-forming] subunit 
beta, mitochondrial
3.6
Catalyzeds the 
GTP-dependent ligation of 
succinate and CoA to form 
succinyl-CoA.
NM_021644.2 P31942
*Heterogeneous Nuclear 
Ribonucleoprotein
H3 (2H9) (HNRPH3), 
transcript variant
2H9A
3.3
Involved in splicing and 
participates in early heat 
shock-induced splicing arresst
NM_002925.3 O43665
Regulator of G-protein 
signaling 10 (RGS10), 
transcript variant 2
2.3
Inhibits signal transduction by 
increasing the GTPase 
activity of G protein alpha 
subunits. 
NM_002969.2 P53778
mitogen-activated protein 
kinase 12 (MAPK12)
2.2
An essential component of the 
MAP kinase signal 
transduction pathway. 
cascades of cellular responses 
evoked by extracellular 
stimuli such as 
proinflammatory cytokines or 
physical stress 
BC014667.1 P01857
Immunoglobulin heavy
constant gamma 1 (G1m 
marker) (IGHG1)
2.1 Humoral immunity
NM_001744.2 Q16566
*calcium/calmodulin-depen
dent protein kinase IV 
(CAMK4)
2.1
calcium/calmodulin-dependen
t protein kinase that operates 
in the calcium-triggerd 
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CaMKK-CaMK4 signaling 
cascade. 
NM_024641.2 Q5SRI9
Glycoprotein 
endo-alpha-1,2-mannosidas
e
2.1
Hydrolysis of the terminal 
alpha-D-glucosyl-(1,3)-D-ma
nnosyl unit from the 
GlcMan9(GlcNAc)2 
oligosaccharide component of 
the glycoprotein produced in 
the Golgi membrane
NM_022476.1 Q9H8T0
AKT interacting protein 
(AKTIP), transcript variant 
2
2.1
Promote vesicle trafficking 
and/or fusion via the 
homotypic vesicular protein 
sorting complex (the HOPS 
complex). Regulates 
apoptosis by enhancing 
phosphorylation and 
activation of AKT1. Increases 
release of TNFSF6 via the 
AKT1/GSK3B/NFATC1 
signaling cascade.
BC027465.1 Q8N647
cDNA clone 
IMAGE:4155919, complete 
cds
2 unknown
NM_016009.2 Q9Y371
SH3-domain GRB2-like 
endophilin B1 (SH3GLB1)
2
May be required for normal 
outer mitochondrial 
membrane dynamics
Protein information was obtained from http://www.uniprot.org/.
Proteins for which the ProtoArray® signal intensity was more than 2-fold 
higher in the patients with bilateral S-SNHL than in the controls are listed (p < 
0.05). *; proteins that were reported to exist in the inner ear sensory 
epithelium. 
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Figure 1. Difference in signal intensity of controls and patients in the 
ProtoArray® experiment. Normalized signal intensities of the antigens with 
a signal intensity more than 5-fold higher in the patients with bilateral 
S-SNHL than in the controls are presented. CXCL10, C-X-C motif chemokine
10; PTK6, protein tyrosine kinase 6; SNX13, sorting nexin 13; TMEM66, 
transmembrane protein 66; CCL4, chemokine (C-C motif) ligand 4; ZCCHC6, 
zinc finger; CCHC, domain containing 6; GH2, growth hormone 2. 
3. Immune reaction of inner ear tissue antigens with patient sera 
Western blotting was performed to investigate whether circulating autoAbs 
from patients with bilateral S-SNHL could produce an Ag-Ab reaction with 
antigens in the inner ear tissue. As a result, bands corresponding to molecular 
weights of 63–75 kDa and 35–48 kDa were commonly detected in the western 
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blots between the patients’ sera and the inner ear tissues, whereas these bands 
were not generally visible in those between sera from the controls and the 
inner ear tissues. 
Bands corresponding to a molecular weight of 63–75 kDa were detected in 
all of the patients and in 2 of the controls (yellow arrows in Figure 2). They 
were detected both in the cochlear and vestibular tissues in 8 of the 10 
samples from patients with bilateral S-SNHL; however, one sample each 
showed the band only in the vestibule and cochlea, respectively. 
Bands located between 35–48 kDa were detected in 7 of the patients with 
bilateral S-SNHL and in 2 of the controls (red arrows in Figure 2). They were 
detected both in the cochlear and vestibular tissues in 4 of the 7 patients, and 
the others were detected only in the vestibular tissues of 3 patients. The bands 
were detected only in the cochlea in 1 of the controls, and in both the cochlea 
and vestibule in 1 control subject. Next, we examined target antigens 
identified in the ProtoArray® experiment, which had molecular weights of 
35–48 kDa and 63–75 kDa. As a result, following proteins had molecular 
weights in the range of interest: PTK6 (51.8 kDa), SUCLG2 (46.5 kDa), 
MICB (42.7 kDa), MAPK12 (41.9 kDa), SH3GLB1 (40.8 kDa), TMEM66 
(37 kDa), HNRPH3 (36.9 kDa), and IGHG1 (36.1 kDa). These Ags may 
potentially be involved in inner ear autoimmune reactions. 
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Figure 2. Western blot of the reaction of serum from controls and patients 
with mouse inner ear. Red and blue arrows represent the detected inner ear 
antigens with molecular weights of 63-75 kDa and 35-48 kDa. C, control; P, 
patient; Co, mouse cochlear tissue protein; V, mouse vestibular tissue protein. 
4. Candidate inner ear antigens for the autoimmune reaction identified by 
immunoprecipitation and LC-MS/MS
LC-MS/MS was performed to identify differences in the protein composition 
of immune complexes in controls and patients with bilateral S-SNHL, which 
could provide clues to identify disease-specific autoAbs and their target inner 
ear antigens. It was performed with the Ag-Ab complexes acquired from 
immunoprecipitation followed by 1-DE. As the proteins of Ag-Ab complexes 
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identified by western blotting corresponded to the molecular weight of 35–48 
kDa and 63–75 kDa, the bands located in those areas were excised and the 
proteins in those bands were concentrically analyzed (Figure 3). In the 
LC-MS/MS analysis, a total of 292 (patient 1), 849 (patient 2), 846 (control 2), 
and 166 (control 3) proteins were detected in the 35–48 kDa range, and a total 
of 560 (patient 1), 590 (patient 2), 1488 (patient 3), 1357 (patient 4), 1808 
(control 1), 822 (control 2), 311 (control 3), and 1704 (control 4) proteins 
were detected in the 63-75 kDa range. 
Figure 3. Representative figure of 1-DE for the acquisition of proteins of 
immune complexes from patients and controls. C, control; P, patient. 
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The proteins commonly and exclusively found in LC-MS/MS of patients 
with bilateral S-SNHL were analyzed and compared to those found in 
LC-MS/MS of controls. Consequently, a total of 32 proteins in the 35–48 kDa 
range and 9 proteins in the 63–75 kDa range were identified (Table 3); these 
proteins were mostly immunoglobulin and its variants (35, 85.4%), which are 
speculated to be candidate autoAbs. These proteins were followed by 
hypothetical protein (3, 7.3%), albumin (1, 2.4%), CD5 antigen-like precursor 
(1, 2.4%), and haptoglobin (1, 2.4%). These proteins, with molecular weights 
of 35–48 kDa and 63–75 kDa, were possibly found from the result of the 
autoimmune and/or enhanced immune reactions in the inner ear. However, 
there was a discrepancy between the results of the LC-MS/MS and 
ProtoArray® experiments; the proteins detected in the LC-MS/MS were not 
identified in the ProtoArray® experiment.
Table 3. Proteins identified only in the sera of bilateral S-SNHL patients by 
LC-MS/MS 
Access No. Description (Taxonomy) MW(kDa)
sequence 
coverage 
(%)
Peptide 
score
gi|10334625 immunoglobulin heavy chain [Homo sapiens] 35-48 21 44.9
gi|10334541 immunoglobulin heavy chain [Homo sapiens] 35-48 29 44.9
gi|10334555 immunoglobulin heavy chain [Homo sapiens] 35-48 29 44.9
gi|10334587 immunoglobulin heavy chain [Homo sapiens] 35-48 29 33.4
gi|10334611 immunoglobulin heavy chain [Homo sapiens] 35-48 21 44.9
gi|10334619 immunoglobulin heavy chain [Homo sapiens] 35-48 21 44.9
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gi|229536 Ig A L 35-48 23 51.4
gi|229585 Ig A1 Bur 35-48 18 45.6
gi|70058 Ig alpha-2 chain C region - human 35-48 20 68.7
gi|229601 Ig G1 H Nie 35-48 34 37.5
gi|21410208 IGL@ protein [Homo sapiens] 35-48 33 38.5
gi|587348
immunoglobulin kappa light chain variable region 
[Homo sapiens]
35-48 15 98.8
gi|170684534
immunoglobulin lambda 2 light chain [Homo 
sapiens]
35-48 34 44.9
gi|229528 protein Len,Bence-Jones 35-48 19 33.4
gi|229526 protein Rei,Bence-Jones 35-48 32 44.3
gi|384376630
7A13 anti-H3N2 influneza HA immunoglobulin 
lambda chain, partial [Homo sapiens]
35-48 11 57.6
gi|146387531
* Chain A, Crystal Structure Of An Autoimmune 
Complex Between A Human Igm Rheumatoid 
Factor And Igg1 Fc Reveals A Novel Fc Epitope 
And Evidence For Affinity Maturation
35-48 31 37.5
gi|8569502
Chain A, Fc Fragment Of Human Igg1 In Complex 
With An Engineered 13 Residue Peptide 
Dcawhlgelvwct-Nh2
35-48 49 37.5
gi|166007160
Chain C, Solution Structure Of Human 
Immunoglobulin M
35-48 23 37.5
gi|230581
Chain H, Dir Primaerstruktur Des Kristallisierbaren 
Monoklonalen Immunoglobulins Igg1 Kol. Ii. 
Aminosaeuresequenz Der L- Kette, Lambda-Typ, 
Subgruppe I (German)
35-48 26 44.9
gi|401871522
* Chain L, Crystal Structure Of A 
Disease-Associated Anti-Human Gm-Csf 
Autoantibody Mb007
35-48 36 38.5
gi|315583384
Chain L, Crystal Structure Of Anti-Il-15 Antibody In 
Complex With Human Il-15
35-48 37 38.5
gi|353251918
Chain L, Crystal Structure Of Broad And Potent 
Hiv-1 Neutralizing Antibody Pgt127 In Complex 
With Man9
35-48 37 38.5
gi|353251927
Chain L, Crystal Structure Of Broad And Potent 
Hiv-1 Neutralizing Antibody Pgt128 In Complex 
With A Glycosylated Engineered Gp120 Outer 
Domain With Miniv3 (Eodmv3)
35-48 37 38.5
gi|353251903
Chain L, Crystal Structure Of Broad And Potent 
Hiv-1 Neutralizing Antibody Pgt128 In Complex 
With Man9
35-48 37 38.5
gi|42543068
Chain L, Crystal Structure Of Human Factor Ix Gla 
Domain In Complex Of An Inhibitory Antibody, 
10c12
35-48 37 38.5
gi|238537877
* Chain L, Crystal Structure Of The Fab Fragment 
Of Anti-Cd20 Antibody Ofatumumab
35-48 21 48.5
gi|442828
Chain L, Structure Of A Human Monoclonal 
Antibody Fab Fragment Against Gp41 Of Human 
Immunodeficiency Virus Type I
35-48 40 59.3
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gi|5174411 CD5 antigen-like precursor [Homo sapiens] 35-48 9 77.1
gi|1620396 haptoglobin [Homo sapiens] 35-48 2 52.9
gi|16554039
unnamed protein product [Homo sapiens]: 
immunoglobulin like
35-48 9 37.5
gi|34527425
unnamed protein product [Homo sapiens]: 
immunoglobulin like
35-48 22 37.5
gi|2414494
immunoglobulin heavy chain, constant region 
[Homo sapiens]
63-75 19 37.9
gi|371446827
immunoglobulin G heavy chain variable region, 
partial [Homo sapiens]
63-75 20 6.9
gi|371447905
immunoglobulin G heavy chain variable region, 
partial [Homo sapiens]
63-75 40 32.5
gi|304562906
immunoglobulin gamma 1 heavy chain variable 
region [Homo sapiens]
63-75 26 32.5
gi|229537 Ig A H 63-75 18 47.1
gi|7439150 Ig mu chain C region - human 63-75 5 23.9
gi|119602344 hCG2038942, partial [Homo sapiens] 63-75 5 23.9
gi|28592 serum albumin [Homo sapiens] 63-75 22 19.7
gi|33451
unnamed protein product [Homo sapiens]: Ig heavy 
chain
63-75 24 21.1
Protein searches were conducted in MASCOT (version 2.2.04) using the 
NCBI database. The search parameters were as follows: 1) Enzyme specificity 
– Trypsin; 2) Maximum missed cleavages – 1; 3) Carbamidomethyl ©; 
Oxidation (M); MASCOT results were filtered using a protein probability 
value of less than 0.05, translating to a false discovery rate of 0.95%. MW; 
molecular weight. *: proteins that were reported to be involved in 
autoimmune disorders.
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IV. DISCUSSION
Several studies have proposed a number of inner ear target antigens and 
corresponding autoAbs for the autoimmune pathology in S-SNHL. However, 
those results were not observed in the context of hearing loss that occurred 
bilaterally and suddenly,19-21 and the subjects in several studies had other 
co-occurring systemic autoimmune diseases.22,23 Although the number of 
patients enrolled in the current study was small, we found reliable evidence 
for the existence of autoimmune reactions and possible target antigens in 
patients with bilateral S-SNHL by mass screening of the target antigens and 
investigating the protein composition of the actual Ag-autoAb complexes 
from patients and controls. Most of these methods have not been adapted in 
previous experiments, and to our knowledge, this is the first study to 
investigate target proteins with mass screening. In addition, we provided a 
possibility for the development of diagnostic biomarkers of autoimmune inner 
ear disorder by the identification of candidate target antigens that showed 
significantly increased immune reactions with the patients’ sera. 
1. Presence of circulating autoAbs and their target antigens 
(ProtoArray® analysis) 
Protein microarrays have previously been used for the detection of autoAbs 
in patients with suspected autoimmune disorders, such as inflammatory bowel 
disease, ovarian cancer, type I diabetes, and multiple sclerosis, and have 
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shown promising results.10,24-26 In an attempt to identify the presence of 
autoAbs in patients with bilateral S-SNHL, we evaluated the autoimmune 
profiles of a limited cohort of patients and controls using a ProtoArray®
containing 9,400 human proteins as target antigens. Consequently, 20 antigens 
were identified to which the patient group had more than 2-fold higher signal 
intensity than controls; among these, 7 antigens showed more than 5-fold 
higher signal intensity. Although the exact location or function of these 
proteins is not fully understood, they were assumed to play various roles such 
as in cell signaling, humoral and cellular immunity, growth control, and 
maintenance of neurotransmitter release sites in specific cell types and tissues.
However, the functions of one protein, cDNA clone IMAGE:4155919, remain 
unknown. Among the proteins, mRNAs of DPEP2, HNRPH3, and CAMK4 
have been reported to exist in the inner ear sensory epithelium and ribbon 
synapse,27 strongly suggesting their potential role as candidate target antigens. 
The definite role of each protein has not been identified. Among the proteins, 
HRNPH3 was identified as an autoantigen for acute anterior uveitis.28 This 
protein was identified to exist in the inner ear sensory epithelium; although its 
functional relevance in the inner ear remains unclear. It is reported to be 
involved in splicing and heat-shock-induced splicing arrest, which suggests 
genetic causes for autoimmune hearing loss. The other protein, MICB, was 
also revealed to be involved in immune reactions, although it has not been 
identified in the inner ear. MICB acts as a stress-induced self-antigen that is 
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recognized by gamma delta T cells.29 MICB belongs to a family of 
“stress-induced” major histocompatibility complex (MHC) class I-like 
proteins, which are generally expressed in normal tissues and monocytes. It 
can be induced by stress, such as heat shock, oxidative stress, or viral and 
bacterial infections, and is regarded to play an important role in immune 
regulation in the pathogenesis of systemic lupus erythematous.30 Although the 
existence of MICB in the inner ear has not yet been verified, it can be a target
antigen for autoimmune reactions in the specific cell types of the inner ear 
and/or an indirect evidence for increased immune reaction by increased 
expression in the immune-mediating cells. IGHG1, which is involved in 
humoral immunity, showed a 2.1-fold higher intensity in the experiment. 
Interestingly, enhanced immune reaction associated with IGHG1 has been 
reported in patients with Meniere’s disease31. A previous study explains the 
phenomenon by the presence of circulating immune complexes and an 
excessive autoimmune/inflammatory reaction in the inner ear. As Meniere’s 
disease and sudden SNHL share many similarities, increased reaction with 
IGHG1 in this study can support the possibility of autoimmune or increased 
immune reaction. 
The results from the ProtoArray® experiment suggest the presence of 
circulating autoAbs in patients’ sera and candidate target antigens for bilateral 
S-SNHL. 
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2. Immune reaction between circulating autoAbs and antigens of the 
inner ear
In the next step, western blotting was performed to demonstrate if the 
circulating autoAbs could induce an immune reaction with proteins in the 
inner ear. The results showed exclusive presence of an immune reaction 
between the two proteins in the patient group. Animal inner ear antigens that 
have been reported to react with sera from patients with bilateral S-SNHL 
have molecular weights in the 42, 58, 68, and 72 kDa ranges.32,33 Consistent 
with previous findings, the results of the present study showed similar 
reactions, especially with proteins with molecular weights in the 63–75 kDa 
and 35–48 kDa ranges. The greater part of candidate proteins from the 
ProtoArray® had molecular weights of 35-48 kDa, while the Ag-Ab reaction 
was most frequent for proteins in the 63–75 kDa range. This discrepancy was 
likely to be due to several causes. First, the ProtoArray® system consists of 
human amino acid sequences for target antigens; however, we used mouse 
inner ear proteins for the western blot experiment for ethical reasons. 
Although a large portion of the epitope for Ag-Ab reactions overlapped 
between the human and mouse inner ear, there remains a possibility that the 
human and mouse inner ear proteins have different epitopes. Second, since the 
candidate target antigens from the ProtoArray® were determined by selecting 
the proteins that showed more than 2-fold higher signal intensity in patients 
with bilateral S-SNHL than in the controls, the target antigens that showed a 
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smaller increase in the signal intensity could be neglected. As observed in all 
the screening methods such as microarray and mass spectrometry, there may 
be a possibility of false-positive and false-negative results in the ProtoArray®
due to denatured or inactive conformations of the arrayed proteins.34 Despite 
the discrepancy between the two experiments, it was strongly suspected in our 
results that the proteins with molecular weights in the 63-75 kDa and 35-48 
kDa ranges could be the main candidates for autoimmune causes for bilateral 
S-SNHL.
Among the twenty candidate proteins obtained from the ProtoArray®
experiment, 8 proteins weigh around 35–48 kDa: PTK6, TMEM66, MICB, 
SUCLA2, HNRPH3, MAPK 12, IGHG1, and SH3GLB1. In particular, as 
HNRPH3 is known to be expressed in the inner ear, its role as a candidate 
antigen is more likely. We have shown the reaction between circulating 
autoAbs and inner ear tissue through western blotting, and found consistent 
responses among the patients to common candidate antigens. 
3. Identification of candidate inner ear target antigens by IP and 
LC-MS/MS
Finally, we attempted to analyze the protein composition of actual Ag-Ab 
complexes from patients and control groups to identify candidate antigens 
and/or autoAbs. In addition, we tried to validate if the proteins identified 
through LC-MS/MS matched those identified through the ProtoArray®
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experiment.
As a result, the most common proteins encountered exclusively in the patient 
group were immunoglobulins and their variants, which were likely to be 
candidate autoAbs for the autoimmune reaction. The presence of increased 
immunoglobulins and their variants could support the evidence of increased 
immune reaction in the patients with bilateral S-SNHL. Among these 
immunoglobulins and their variants, few proteins were identified to be 
involved in several autoimmune disorders. The chain A from human 
immunoglobulin M rheumatoid factor (gi|146387531) forms an autoimmune 
complex in patients with rheumatoid arthritis.35 Partial chain of anti-human 
granulocyte-macrophage colony-stimulating factor (GM-CSF) autoAb 
(gi|401871522) was shown in the experiment, and the polyclonal autoAb 
against human GM-CSF is known as a hallmark of pulmonary alveolar 
proteinosis and several other reported autoimmune diseases.36 CD 20 is a 
B-lymphocyte antigen that is expressed on the surface of all B-cells during the 
pro-B phase. Its function is to enable optical B-cell immune response; hence,
synthetic monoclonal CD20 antibodies are now used to treat certain B-cell 
lymphomas and autoimmune diseases.37 A fragment of the anti-CD20 Ab 
(gi|238537877) was found in the experiment, and the presence of the antibody 
could support its possibility as an autoimmune disease in bilateral S-SNHL. 
However, immunoglobulin variants are the most commonly found proteins in 
the serum, and it is possible that some portion of the identified 
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immunoglobulin could be a product of contamination. The other proteins such 
as serum albumin and haptoglobin could also be the result of contamination,
as they are one of the most abundant blood plasma proteins, and are
frequently found to be non-specific ones in experiments using blood samples. 
Furthermore, we did not try to remove nonspecific abundant antigens such as 
serum albumin and immunoglobulin by using multiple affinity removal 
columns during the experiment because this procedure could also remove 
autoAbs. There were three unnamed proteins; two (gi|16554039, gi|34527425) 
were revealed to be immunoglobulin-like proteins, and the other (gi|33451) 
was revealed to be the Ig heavy chain. While these proteins could be 
candidate autoAbs, they could be also non-specific ones. However, we could 
detect several proteins for the target antigens other than immunoglobulin and 
their variants, albumin, and haptoglobin. The CD5 antigen-like precursor, 
which was exclusively found in the patient group, is mainly involved in 
immune system processes, cellular defense, or inflammatory responses,38 and 
it could be a target antigen for the immune reaction between circulating 
antibodies and inner ear antigens. Consequently, the proteins detected from 
the patient group support the possibility of autoimmunity as a cause of 
increased immune and inflammatory reactions in the inner ear. 
It was found that the proteins detected through the ProtoArray® and those 
detected through the LC-MS/MS hardly match. This could be due to different 
characteristics of the two different experimental techniques for the detection 
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of proteins. The ProtoArray® used the Ag-Ab reaction between the patient’s 
serum and protein sequences embedded on the chip and detects only increased 
immune reactions comparing the experimental and control samples. Even 
though the circulating autoAbs existed in the patient’s serum, the results could 
be negative if the immune reaction between the serum and the target antigen
sequence did not have high signal intensity for detection. LC-MS/MS cannot 
be used to identify differences in the protein expression level or protein signal 
intensity between the two groups. Instead, it can only identify the list of 
proteins that exist in the samples that are provided. Therefore, we could not 
compare the differences in the expression of specific proteins between the two 
samples, and could only identify the proteins that exclusively exist in one 
sample by comparing the lists of proteins in the two samples. In addition, 
LC-MS/MS detects proteins by analyzing the sample molecules broken into 
charged ions using statistical methods that correlate known masses with the 
identified masses through a characteristic fragmentation pattern. Therefore, 
there should be false negative results even though certain proteins exist in the 
samples. Although the p values in the mass spectrometry analysis were less 
than 0.05, only 14 proteins over 30%, and 26.8% (11 proteins) showed protein 
sequence coverage of under 10% in our mass spectrometry data (Table 3). 
Lower protein sequence coverage implies lesser possibility of being the
candidate protein, although the possibility of false result was not high when 
unique amino acid sequences identified by LC-MS/MS were considered. 
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In summary, based on the assumption that bilateral S-SNHL is an 
autoimmune disease, we performed mass screening of patients with bilateral 
S-SNHL using several approaches. We proved the existence of circulating 
autoAbs and investigated several possible candidate antigens from the 
ProtoArray®. Western blotting confirmed the presence of an immune reaction 
between the circulating autoAbs and the inner ear tissues by showing 
consistent responses to common candidate antigens. Finally, LC-MS/MS was 
used to investigate a few possible candidate antigens and/or autoAbs with 
enhanced immune reactions. From these studies, it can be concluded that 
autoimmune reactions are a major pathological process underlying the disease, 
and multiple target antigens and autoAbs, rather than a single Ag-Ab
combination, may be responsible for the autoimmune reaction associated with 
bilateral S-SNHL. However, in the absence of peptide sequencing, we cannot 
determine whether a particular protein is a specific antigen involved in an 
immune reaction.
4. Clinical implication and future direction
Autoimmunity as a pathological mechanism of hearing loss has been 
suspected in many cases, especially if the hearing loss is bilateral, progressive, 
and the patient has a history of autoimmune disorder or positive autoimmune 
profiles in the laboratory tests; however, the diagnostic method still remains 
unclear, which can delay proper management. In the future, definite 
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diagnostic method for autoimmune hearing loss should be developed for 
proper treatment and anticipation of patient’s prognosis. Bilateral S-SNHL is a 
good model for investigating the evidence and pathologic mechanism of 
autoimmune hearing loss. In this study, we investigated the evidence of 
autoimmune reaction, the candidate antigens, and autoAbs and provided 
evidences for the autoimmunity as one of the pathologic mechanisms for 
bilateral S-SNHL. The results of this study can provide a basis for the 
diagnosis of autoimmune hearing loss. The development of highly sensitive 
diagnostic chips using multiple definite target antigens enables the accurate 
diagnosis of autoimmune hearing loss and proper management using 
anti-inflammatory or immune suppressive agents, which can finally delay the 
progression of autoimmune-induced hearing loss. In cases where autoimmune 
hearing loss, especially bilateral S-SNHL, several other causes such as genetic 
and central disorders should be ruled out before the decision of treatment 
methods. The multi-array diagnostic chip using biomarkers for autoimmunity 
enables differential diagnosis of the disease if combined with careful 
neurological examinations and history taking of family histories. However, to 
applicate these proteins as biomarkers for the bilateral S-SNHL, mass 
screening for multiple proteins in large population should be conducted and 
this effort can promise the improvement of diagnosis of autoimmune-related 
inner ear disorder. 
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V. CONCLUSION
The findings of this study suggest that autoimmunity could be one of the 
pathologic mechanisms underlying bilateral S-SNHL. Multiple antigens and 
autoAbs may be involved in the autoimmune reaction. Specific antigens 
identified to cause immune reactions with patient serum in ProtoArray®
analysis may be candidates for diagnostic biomarkers of bilateral S-SNHL.
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ABSTRACT (IN KOREAN)
양측성 돌발성 난청 환자에서
프로테오믹스(Proteomics)를 이용한 자가 면역 반응의 규명
< 지도교수 김 성 헌 >
연세대학교 대학원 의학과
이 전 미
돌발성 난청은 특별한 원인 없이 3일 이내에 3개 이상의 연속된
주파수에서 30dB이상의 감각신경성 청력 손실이 발생하는 것으로, 
대부분 일측성으로 발생하지만 아주 드물게 양측성으로 나타나기도
한다. 현재까지 돌발성 난청의 원인에 대하여 정확하게 밝혀진 바는
없으나 다양한 가설들이 제기되고 있으며, 특히 양측성 돌발성 난
청에서 자가 면역 반응이 원인일 수 있다는 보고가 있다. 이에 본
논문에서는 기존의 연구를 토대로 자가 면역 반응이 양측성 돌발성
난청의 원인일 수 있다는 가설 하에 그 근거를 찾고 원인 항원 및
항체를 밝혀, 질병의 기제를 이해하고 나아가 진단에 활용할 수
있는 생물 지표를 제공하고자 한다. 
본 연구에서는 10명의 양측성 돌발성 난청 환자 및 10명의 정상
대조군에서 채취한 혈액을 이용하여 다양한 단백질체학적 접근을
통해 가설을 증명하고자 하였다. 첫째로 ProtoArray® 기법을
이용하여 상용화 된 9,400개의 인체 단백질과 혈청을 반응시켜
환자군에서 자가 항체의 존재를 확인하고, 이 항체들과 반응하는
후보 항원을 규명하였다. 이어 western blot 기법을 이용하여
환자군에 존재하는 자가 항체가 실제 내이 조직과 면역반응을
일으킴을 증명하였으며, 그 과정 중 환자군에서 공통적으로 반응을
보이는 항원이 존재함을 확인하였다. 마지막으로 고속 액체
크로마토 그래프 질량 분석법(LC-MS/MS)을 이용하여 실제 반응을
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일으킨 항원-항체 면역복합체를 분리하고 분석하여 환자군에서 면역
반응이 증가되어 있음을 확인하고, 그 후보 자가 항체를 확인할 수
있었다. 세 단계의 시험 과정 중 중복되는 단백질 8개를 추려낼 수
있었으며, 이는 강력한 후보 항원 및 후보 자가 항체로 여겨진다. 
본 연구를 통하여 자가 면역 반응이 양측성 돌발성 난청의 주요
원인임을 밝히고, 그 원인 항원 및 항체로 여겨지는 단백질을
검출하였다. 향후 이들을 이용하여 질병의 진단 및 경과에 대한
이해를 높일 수 있을 것으로 기대된다. 
--------------------------------------------------------------------------------------
핵심되는 말: 양측성 돌발성 감각신경성 난청, 자가 면역 질환, 
내이, 자가 항체
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